Skip to content

Trial Summary

The Myeloma 1000 Project aims to establish a repository of blood specimens available for future assessment of circulating biomarkers that better predict treatment response, and individuals at risk of developing myeloma and accelerated disease progression.

Acronym:

Myeloma 1000

ACTRN/NCT /ethics:

n/a

Scientific title:

The Myeloma 1000 Project: a blood biobank of the MRDR

Sponsor / Cooperative group:

Amgen Australia, Bristol Myers Squibb and Janssen

Trial & Patient Characteristics

Cancer TypeOther
Trial TypeEarly detection, diagnosis, prognosis
PhaseAll phases
Age Range18 years and older
SexBoth
Tumour Stream Myeloma
Cancer StageAll stages
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Stanley Cheung
Recruitment StatusNot Yet Recruiting